The 2026 cell and gene therapy predictions article highlights how the advanced therapy sector is shifting from scientific promise to industrial maturity, with a strong focus on scalability, cost control and broader patient access in 2026. Leaders predict priorities such as data-driven development, digital integration in manufacturing, and flexible solutions that support cost-efficient scale-up across the ecosystem.

Contributions from TTP plc colleagues:

Stuart Lowe (Head of Advanced Therapies, TTP plc): Stuart emphasises that data-driven development will become essential as cell and gene therapy modalities diversify and cost pressures intensify, including using technologies such as large language models to improve digital process design and efficiency.

Douglas Bradshaw (Head of Business Development, TTP plc): Douglas highlights that the CGT sector will accelerate investment in technologies and platforms that enable scalable, cost-efficient manufacturing in 2026, pointing to the growing demand for scalable manufacturing and process solutions as the industry matures.

Read the full article on Cell and Gene Therapy Review.